These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24304170)

  • 1. Absorption, metabolism and excretion of [14C]gemigliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.
    Kim N; Patrick L; Mair S; Stevens L; Ford G; Birks V; Lee SH
    Xenobiotica; 2014 Jun; 44(6):522-30. PubMed ID: 24304170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absorption, distribution, metabolism and excretion of gemigliptin, a novel dipeptidyl peptidase IV inhibitor, in rats.
    Kim Y; Kim U; Kim IS; Lee SH; Lee J; Kim DH; Yoo HH
    Xenobiotica; 2014 Jul; 44(7):627-34. PubMed ID: 24738939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.
    Noh YH; Lim HS; Jin SJ; Kim MJ; Kim YH; Sung HR; Choi HY; Bae KS
    Clin Ther; 2012 May; 34(5):1182-94. PubMed ID: 22534255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects.
    Park SI; Lee H; Oh J; Lim KS; Jang IJ; Kim JA; Jung JH; Yu KS
    Drug Des Devel Ther; 2015; 9():729-36. PubMed ID: 25678778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of renal impairment and haemodialysis on the pharmacokinetics of gemigliptin (LC15-0444).
    Shon JH; Kim N; Park SJ; Oh MK; Kim EY; Lee SH; Kim YH; Shin JG
    Diabetes Obes Metab; 2014 Oct; 16(10):1028-31. PubMed ID: 24641348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
    Kim SH; Jung E; Yoon MK; Kwon OH; Hwang DM; Kim DW; Kim J; Lee SM; Yim HJ
    Eur J Pharmacol; 2016 Oct; 788():54-64. PubMed ID: 27298192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans.
    Furuta S; Smart C; Hackett A; Benning R; Warrington S
    Xenobiotica; 2013 May; 43(5):432-42. PubMed ID: 23075005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans.
    Nakamaru Y; Hayashi Y; Ikegawa R; Kinoshita S; Perez Madera B; Gunput D; Kawaguchi A; Davies M; Mair S; Yamazaki H; Kume T; Suzuki M
    Xenobiotica; 2014 Mar; 44(3):242-53. PubMed ID: 23855261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism, excretion, and pharmacokinetics of ((3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human.
    Sharma R; Sun H; Piotrowski DW; Ryder TF; Doran SD; Dai H; Prakash C
    Drug Metab Dispos; 2012 Nov; 40(11):2143-61. PubMed ID: 22896728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.
    He H; Tran P; Yin H; Smith H; Batard Y; Wang L; Einolf H; Gu H; Mangold JB; Fischer V; Howard D
    Drug Metab Dispos; 2009 Mar; 37(3):536-44. PubMed ID: 19074975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans.
    Vincent SH; Reed JR; Bergman AJ; Elmore CS; Zhu B; Xu S; Ebel D; Larson P; Zeng W; Chen L; Dilzer S; Lasseter K; Gottesdiener K; Wagner JA; Herman GA
    Drug Metab Dispos; 2007 Apr; 35(4):533-8. PubMed ID: 17220239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
    Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T
    Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry.
    Kim SH; Lee SH; Yim HJ
    Arch Pharm Res; 2013 Oct; 36(10):1185-8. PubMed ID: 23771499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic Interactions Between Gemigliptin and Metformin, and Potential Differences in the Pharmacokinetic Profile of Gemigliptin Between the Mexican and Korean Populations: A Randomized, Open-label Study in Healthy Mexican Volunteers.
    Conde-Carmona I; García-Medina S; Jiménez-Vargas JM; Martínez-Muñoz A; Lee SH
    Clin Ther; 2018 Oct; 40(10):1729-1740. PubMed ID: 30249366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans.
    Blech S; Ludwig-Schwellinger E; Gräfe-Mody EU; Withopf B; Wagner K
    Drug Metab Dispos; 2010 Apr; 38(4):667-78. PubMed ID: 20086031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic comparison of gemigliptin 50 mg and metformin 500 mg as a fixed-dose combination and loose combination
.
    Lee SW; Park SI; Lee S; Chung JY; Yu KS
    Int J Clin Pharmacol Ther; 2019 Feb; 57(2):117-124. PubMed ID: 30574864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects.
    Shin D; Cho YM; Lee S; Lim KS; Kim JA; Ahn JY; Cho JY; Lee H; Jang IJ; Yu KS
    Clin Drug Investig; 2014 Jun; 34(6):383-93. PubMed ID: 24627290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study.
    Yang E; Yoo H; Jang IJ; Yu KS; Lee S
    Drug Des Devel Ther; 2021; 15():651-658. PubMed ID: 33628012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemigliptin, a novel dipeptidyl peptidase-4 inhibitor, exhibits potent anti-glycation properties in vitro and in vivo.
    Jung E; Kim J; Kim SH; Kim S; Cho MH
    Eur J Pharmacol; 2014 Dec; 744():98-102. PubMed ID: 25448307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disposition and metabolism of 14C-rifapentine in healthy volunteers.
    Reith K; Keung A; Toren PC; Cheng L; Eller MG; Weir SJ
    Drug Metab Dispos; 1998 Aug; 26(8):732-8. PubMed ID: 9698286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.